The European Narcolepsy Network (EU‐NN) database

Narcolepsy with cataplexy is a rare disease with an estimated prevalence of 0.02% in European populations. Narcolepsy shares many features of rare disorders, in particular the lack of awareness of the disease with serious consequences for healthcare supply. Similar to other rare diseases, only a few European countries have registered narcolepsy cases in databases of the International Classification of Diseases or in registries of the European health authorities. A promising approach to identify disease‐specific adverse health effects and needs in healthcare delivery in the field of rare diseases is to establish a distributed expert network. A first and important step is to create a database that allows collection, storage and dissemination of data on narcolepsy in a comprehensive and systematic way. Here, the first prospective web‐based European narcolepsy database hosted by the European Narcolepsy Network is introduced. The database structure, standardization of data acquisition and quality control procedures are described, and an overview provided of the first 1079 patients from 18 European specialized centres. Due to its standardization this continuously increasing data pool is most promising to provide a better insight into many unsolved aspects of narcolepsy and related disorders, including clear phenotype characterization of subtypes of narcolepsy, more precise epidemiological data and knowledge on the natural history of narcolepsy, expectations about treatment effects, identification of post‐marketing medication side‐effects, and will contribute to improve clinical trial designs and provide facilities to further develop phase III trials.

[1]  G. Plazzi,et al.  A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. , 2011, Sleep medicine.

[2]  M. Mühlethaler,et al.  Rat Hypocretin/Orexin Neurons Are Maintained in a Depolarized State by TRPC Channels , 2010, PloS one.

[3]  E. Mignot,et al.  Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. , 2012, Sleep.

[4]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[5]  P. Jennum,et al.  Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. , 2012, Sleep medicine.

[6]  A. Pariente,et al.  Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. , 2013, Brain : a journal of neurology.

[7]  M. Partinen,et al.  Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland , 2012, PloS one.

[8]  C. Drake,et al.  The prevalence of multiple sleep-onset REM periods in a population-based sample. , 2006, Sleep.

[9]  A. Spottke,et al.  Health-related quality of life in patients with narcolepsy. , 2007, Sleep medicine.

[10]  F. Poli,et al.  Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. , 2013, Vaccine.

[11]  J. Sutcliffe,et al.  The hypocretins/orexins: novel hypothalamic neuropeptides involved in different physiological systems , 1999, Cellular and Molecular Life Sciences CMLS.

[12]  E. Mignot,et al.  Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. , 2014, Sleep.

[13]  N. Guex,et al.  A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. , 2011, American journal of human genetics.

[14]  S. Carr,et al.  Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior , 1998, Cell.

[15]  I. Smith,et al.  Factors associated with a delay in the diagnosis of narcolepsy. , 2004, Sleep medicine.

[16]  S. Carr,et al.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. , 1998, Cell.

[17]  Z. Kutalik,et al.  DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. , 2014, Sleep.

[18]  M. Edwards,et al.  Complex movement disorders at disease onset in childhood narcolepsy with cataplexy , 2011, Brain : a journal of neurology.

[19]  Kiyohisa Takahashi,et al.  Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-naïve patients and the general Japanese population. , 2012, Sleep medicine.

[20]  T. Hökfelt,et al.  Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns , 2014, Proceedings of the National Academy of Sciences.

[21]  T. Young,et al.  Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. , 2014, Sleep.

[22]  R. Daroff,et al.  The International Classification of Sleep Disorders , 1991, Neurology.

[23]  S. Overeem,et al.  The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. , 2011, Sleep medicine.